Sionna Therapeutics, Inc.
Public company- Headquarters
- WALTHAM, Massachusetts
- Ticker
- SION
- CIK
- 0002036042
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Chief Business OfficerCaroline Stark Beer, M.B.A. | Sep 14, 2026 | Departed |
| CMOCharlotte McKee | Sep 14, 2026 | Appointed |
| CFOElena Ridloff | Sep 14, 2026 | Appointed |
| CLOJennifer Fitzpatrick | Sep 14, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ENANTA PHARMACEUTICALS INC
CEO departs: Jay R. Luly, Ph.D.
- VERTEX PHARMACEUTICALS INC / MA
new member of the board of directors appointed: Daniel Brennan
- Ernexa Therapeutics Inc.
member of the Board appointed: Robert J. Spiegel, M.D.
- BRISTOL MYERS SQUIBB CO
WARN notice: Princeton, NJ
- Executive departure
Chief Business Officer departs: Caroline Stark Beer, M.B.A.
Caroline Stark Beer, M.B.A., Chief Business Officer of Sionna Therapeutics, Inc., leaves the role, effective September 15, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 14, 2026Role: Chief Business Officer
- Executive appointment
CMO appointed: Charlotte McKee
Charlotte McKee was named Chief Medical Officer of Sionna Therapeutics, Inc., effective September 16, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 14, 2026Role: Chief Medical Officer
- Executive appointment
CFO appointed: Elena Ridloff
Elena Ridloff was named Chief Financial Officer of Sionna Therapeutics, Inc., effective September 16, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 14, 2026Role: Chief Financial Officer
- Executive appointment
CLO appointed: Jennifer Fitzpatrick
Jennifer Fitzpatrick was named Chief Legal Officer of Sionna Therapeutics, Inc., effective September 16, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 14, 2026Role: Chief Legal Officer
Last verified Nov 8, 2026